☰

add clinical section

rdmorin committed 2026-01-21 15:21:05 -0800 commit 6f99090ee823fba60274574b342556b33b517dda

				EZH2.md
			
          @@ -17,10 +17,12 @@ Although mutations in EZH2 have been described in some BL patients, they are ext

           ## Experimental Evidence

           Mutations at the main hotspot and some less common hotspots lead to enhanced methylation by PRC2.[@yapSomaticMutationsEZH22011]

          +

          +## Clinical relevance

          +

           A number of small molecule/pharmacologic inhibitors of EZH2 activity have been described.[@garapaty-raoIdentificationEZH2EZH12013; @knutsonSelectiveInhibitionEZH22014] At least one of these, tazemetostat, has shown benefit in FL.[@morinTreatingLymphomaNow2021] 

           Combination therapies including EZH2 inhibitors are also under exploration for DLBCL patients with mutant EZH2.[@scholzeCombinedEZH2Bcl22020]

          -

           ## Relevance tier by entity

           [[include:tables/table1_EZH2]]

...	...	@@ -17,10 +17,12 @@ Although mutations in EZH2 have been described in some BL patients, they are ext
17	17	## Experimental Evidence
18	18
19	19	Mutations at the main hotspot and some less common hotspots lead to enhanced methylation by PRC2.[@yapSomaticMutationsEZH22011]
	20	+
	21	+## Clinical relevance
	22	+
20	23	A number of small molecule/pharmacologic inhibitors of EZH2 activity have been described.[@garapaty-raoIdentificationEZH2EZH12013; @knutsonSelectiveInhibitionEZH22014] At least one of these, tazemetostat, has shown benefit in FL.[@morinTreatingLymphomaNow2021]
21	24	Combination therapies including EZH2 inhibitors are also under exploration for DLBCL patients with mutant EZH2.[@scholzeCombinedEZH2Bcl22020]
22	25
23		-
24	26	## Relevance tier by entity
25	27
26	28	[[include:tables/table1_EZH2]]